RU2003134010A - 5-замещенные-2-арилпиридины в качестве модуляторов crf1 - Google Patents
5-замещенные-2-арилпиридины в качестве модуляторов crf1 Download PDFInfo
- Publication number
- RU2003134010A RU2003134010A RU2003134010/04A RU2003134010A RU2003134010A RU 2003134010 A RU2003134010 A RU 2003134010A RU 2003134010/04 A RU2003134010/04 A RU 2003134010/04A RU 2003134010 A RU2003134010 A RU 2003134010A RU 2003134010 A RU2003134010 A RU 2003134010A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- alkoxy
- amino
- independently selected
- halogen
- Prior art date
Links
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 title 1
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 title 1
- 101000948733 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid translocase non-catalytic subunit CRF1 Proteins 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims 72
- 150000002367 halogens Chemical class 0.000 claims 63
- 125000000753 cycloalkyl group Chemical group 0.000 claims 61
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 49
- -1 hydroxy, amino Chemical group 0.000 claims 49
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 239000001257 hydrogen Substances 0.000 claims 40
- 125000004093 cyano group Chemical group *C#N 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 37
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 125000001424 substituent group Chemical group 0.000 claims 34
- 125000004432 carbon atom Chemical group C* 0.000 claims 30
- 150000002431 hydrogen Chemical class 0.000 claims 28
- 125000004043 oxo group Chemical group O=* 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000004076 pyridyl group Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 108091005471 CRHR1 Proteins 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical class 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 238000011534 incubation Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 238000001525 receptor binding assay Methods 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000000376 autoradiography Methods 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 210000003061 neural cell Anatomy 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29270301P | 2001-05-22 | 2001-05-22 | |
| US60/292,703 | 2001-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003134010A true RU2003134010A (ru) | 2005-05-20 |
Family
ID=23125823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003134010/04A RU2003134010A (ru) | 2001-05-22 | 2002-05-22 | 5-замещенные-2-арилпиридины в качестве модуляторов crf1 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7223778B2 (enExample) |
| EP (1) | EP1392302A1 (enExample) |
| JP (1) | JP2004531570A (enExample) |
| KR (1) | KR20040015716A (enExample) |
| AP (1) | AP2003002920A0 (enExample) |
| BG (1) | BG108490A (enExample) |
| BR (1) | BR0209920A (enExample) |
| CA (1) | CA2448198A1 (enExample) |
| EC (1) | ECSP034860A (enExample) |
| HR (1) | HRP20031056A2 (enExample) |
| HU (1) | HUP0400316A2 (enExample) |
| IL (1) | IL158958A0 (enExample) |
| IS (1) | IS7046A (enExample) |
| MX (1) | MXPA03010692A (enExample) |
| NO (1) | NO20035183D0 (enExample) |
| PL (1) | PL367153A1 (enExample) |
| RU (1) | RU2003134010A (enExample) |
| SK (1) | SK15432003A3 (enExample) |
| TN (1) | TNSN03119A1 (enExample) |
| WO (1) | WO2002096421A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2423979C2 (ru) * | 2005-06-17 | 2011-07-20 | АФТ Фармасьютикалз Лимитед | Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей |
| RU2468009C2 (ru) * | 2007-08-01 | 2012-11-27 | Тайсо Фармасьютикал Ко., Лтд. | Ингибитор связывания s1p1 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| AU2003291403A1 (en) * | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| WO2005007627A1 (ja) * | 2003-07-18 | 2005-01-27 | Nihon Nohyaku Co., Ltd. | フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤 |
| JPWO2005040135A1 (ja) * | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| CA2989620C (en) * | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| AU2013205160B2 (en) * | 2007-12-07 | 2016-05-19 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US8785650B2 (en) * | 2012-03-30 | 2014-07-22 | Dow Agrosciences, Llc. | Methods for preparing 3-substituted-6-trifluoromethyl pyridines and methods for using 6-trichloromethyl halogenated pyridines |
| CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
| KR101750453B1 (ko) | 2015-09-11 | 2017-06-23 | 동아대학교 산학협력단 | 손잡이 세정이 가능한 샤워헤드용 방향제어밸브 |
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1147068A (en) | 1966-12-02 | 1969-04-02 | Ici Ltd | Phenyl-pyridine derivatives |
| GB9012017D0 (en) * | 1990-05-30 | 1990-07-18 | Ici Plc | Fungicidal compounds |
| DE4315867A1 (de) * | 1993-05-12 | 1994-11-17 | Hoechst Ag | 3-Chlorpyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Flüssigkristallmischungen |
| DE4323916A1 (de) | 1993-07-16 | 1995-01-19 | Basf Ag | Substituierte 2-Phenylpyridine |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5849758A (en) * | 1995-05-30 | 1998-12-15 | American Cyanamid Company | Herbicidal 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines |
| DE19748439A1 (de) * | 1997-11-03 | 1999-05-06 | Hoechst Ag | 1,6-Disubstituierte Naphthalinderivate und ihre Verwendung in flüssigkristallinen Mischungen |
| ATE307121T1 (de) | 2000-02-16 | 2005-11-15 | Neurogen Corp | Substituierte arylpyrazine |
| AU4368001A (en) * | 2000-03-16 | 2001-09-24 | Neurogen Corporation | 5-substituted arylpyrimidines |
-
2002
- 2002-05-22 KR KR10-2003-7015197A patent/KR20040015716A/ko not_active Withdrawn
- 2002-05-22 MX MXPA03010692A patent/MXPA03010692A/es unknown
- 2002-05-22 EP EP02741732A patent/EP1392302A1/en not_active Withdrawn
- 2002-05-22 CA CA002448198A patent/CA2448198A1/en not_active Abandoned
- 2002-05-22 US US10/154,396 patent/US7223778B2/en not_active Expired - Fee Related
- 2002-05-22 SK SK1543-2003A patent/SK15432003A3/sk unknown
- 2002-05-22 HR HR20031056A patent/HRP20031056A2/hr not_active Application Discontinuation
- 2002-05-22 HU HU0400316A patent/HUP0400316A2/hu unknown
- 2002-05-22 PL PL02367153A patent/PL367153A1/xx not_active Application Discontinuation
- 2002-05-22 WO PCT/US2002/016529 patent/WO2002096421A1/en not_active Ceased
- 2002-05-22 AP APAP/P/2003/002920A patent/AP2003002920A0/en unknown
- 2002-05-22 BR BR0209920-9A patent/BR0209920A/pt not_active Application Discontinuation
- 2002-05-22 RU RU2003134010/04A patent/RU2003134010A/ru not_active Application Discontinuation
- 2002-05-22 IL IL15895802A patent/IL158958A0/xx unknown
- 2002-05-22 JP JP2002592931A patent/JP2004531570A/ja active Pending
-
2003
- 2003-07-08 TN TNPCT/US2002/016529A patent/TNSN03119A1/en unknown
- 2003-11-20 IS IS7046A patent/IS7046A/is unknown
- 2003-11-21 NO NO20035183A patent/NO20035183D0/no not_active Application Discontinuation
- 2003-11-21 EC EC2003004860A patent/ECSP034860A/es unknown
- 2003-12-22 BG BG108490A patent/BG108490A/bg unknown
-
2007
- 2007-05-17 US US11/749,840 patent/US20080107608A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2423979C2 (ru) * | 2005-06-17 | 2011-07-20 | АФТ Фармасьютикалз Лимитед | Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей |
| RU2468009C2 (ru) * | 2007-08-01 | 2012-11-27 | Тайсо Фармасьютикал Ко., Лтд. | Ингибитор связывания s1p1 |
Also Published As
| Publication number | Publication date |
|---|---|
| SK15432003A3 (sk) | 2004-05-04 |
| EP1392302A1 (en) | 2004-03-03 |
| IL158958A0 (en) | 2004-05-12 |
| BR0209920A (pt) | 2004-03-30 |
| MXPA03010692A (es) | 2004-07-01 |
| JP2004531570A (ja) | 2004-10-14 |
| ECSP034860A (es) | 2004-01-28 |
| US20030152520A1 (en) | 2003-08-14 |
| CA2448198A1 (en) | 2002-12-05 |
| HUP0400316A2 (hu) | 2005-02-28 |
| HRP20031056A2 (en) | 2005-08-31 |
| TNSN03119A1 (en) | 2005-12-23 |
| NO20035183D0 (no) | 2003-11-21 |
| US20080107608A1 (en) | 2008-05-08 |
| PL367153A1 (en) | 2005-02-21 |
| WO2002096421A1 (en) | 2002-12-05 |
| KR20040015716A (ko) | 2004-02-19 |
| US7223778B2 (en) | 2007-05-29 |
| IS7046A (is) | 2003-11-20 |
| BG108490A (bg) | 2005-01-31 |
| AP2003002920A0 (en) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102642823B1 (ko) | 모발 성장을 조절하기 위한 조성물 및 방법 | |
| JP2004525942A (ja) | 化合物および方法 | |
| KR20210110817A (ko) | 모발 성장을 조절하기 위한 조성물 및 방법 | |
| US8946227B2 (en) | Piperazine derivatives and methods of use | |
| US20080070922A1 (en) | Combination of Organic Compounds | |
| RU2003136151A (ru) | 2, 5-диарилпиразины, 2, 5-диарилпиридины и 2, 5-диарилпиримидины в качестве модуляторов рецептора кортикотропин-рилизинг-фактора 1 (крф1) | |
| JPH10511075A (ja) | 骨格筋収縮を阻害する酸化窒素種および付加物の使用 | |
| KR20050086594A (ko) | 세포 증식 장애를 위한 인돌린온과 화학요법제의 조합 투여 | |
| RU2474612C2 (ru) | Индуцирование гибели клеток путем ингибирования адаптивного теплового шокового ответа | |
| AU2005222402A1 (en) | Ion channel modulators | |
| BR112021000358A2 (pt) | Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais | |
| CN108884112A (zh) | 姜黄素硼配合物和含有该姜黄素硼配合物的药物 | |
| TW202525792A (zh) | 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物 | |
| KR20230169981A (ko) | 적혈구증가증을 치료하기 위한 조성물 및 방법 | |
| JP6669774B2 (ja) | 筋萎縮の治療に有用な誘導体 | |
| US20040198799A1 (en) | Methods of increasing endogenous testosterone levels | |
| WO2011066864A1 (en) | Method and compositions for inhibition of macrophage migration inhibitory factor (mif) | |
| KR20230169982A (ko) | 리보솜 장애와 관련된 빈혈을 치료하기 위한 조성물 및 방법 | |
| WO2001062765A2 (en) | Small molecule modulators of g protein-coupled receptor six | |
| EP2118048B1 (en) | Male contraceptive | |
| US6420563B1 (en) | Small molecule modulators of G protein-coupled receptor six | |
| MXPA01010489A (es) | Metodo para reducir la susceptibilidad a la formacion de tumores inducidos por la desoxiglucosona y sus precursores. | |
| WO2012047628A2 (en) | Methods of managing blood sugar levels and compositions related thereto | |
| CN115087643B (zh) | 稠和杂环类化合物及其制备方法和医药用途 | |
| CN119584967A (zh) | 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050707 |